Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $52.00 at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) had its price objective lowered by UBS Group to $52.00 in a research report sent to investors on Monday morning, Stock Target Advisor reports.

A number of other analysts also recently weighed in on the stock. Oppenheimer decreased their target price on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an outperform rating for the company in a research report on Thursday, November 10th. SVB Leerink cut their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an outperform rating on the stock in a report on Thursday, November 10th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $52.00 to $46.00 in a report on Monday, November 14th. Wedbush dropped their price objective on Zentalis Pharmaceuticals from $51.00 to $32.00 and set an outperform rating on the stock in a research note on Monday, November 14th. Finally, Guggenheim decreased their target price on Zentalis Pharmaceuticals from $55.00 to $28.00 and set a buy rating for the company in a research report on Friday, November 11th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $46.56.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL opened at $21.20 on Monday. The company has a market capitalization of $1.21 billion, a PE ratio of -4.49 and a beta of 1.90. The company has a 50 day simple moving average of $22.42 and a two-hundred day simple moving average of $25.12. Zentalis Pharmaceuticals has a fifty-two week low of $17.33 and a fifty-two week high of $85.95.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $22.32, for a total value of $279,000.00. Following the sale, the president now directly owns 431,885 shares of the company’s stock, valued at $9,639,673.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 62,500 shares of company stock valued at $1,469,125 over the last ninety days. Company insiders own 19.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Matrix Capital Management Company LP grew its position in shares of Zentalis Pharmaceuticals by 111.5% during the second quarter. Matrix Capital Management Company LP now owns 9,199,973 shares of the company’s stock worth $258,519,000 after purchasing an additional 4,850,694 shares in the last quarter. FMR LLC lifted its stake in shares of Zentalis Pharmaceuticals by 15.3% in the 2nd quarter. FMR LLC now owns 7,776,168 shares of the company’s stock valued at $218,510,000 after purchasing an additional 1,033,474 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Zentalis Pharmaceuticals by 2.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,298,551 shares of the company’s stock worth $120,789,000 after acquiring an additional 100,371 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 2.9% during the 3rd quarter. BlackRock Inc. now owns 3,336,066 shares of the company’s stock worth $72,258,000 after acquiring an additional 95,008 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 3,240,585 shares of the company’s stock worth $149,520,000 after acquiring an additional 53,599 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Further Reading

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.